CommunityDispatch.com
Community News and Information
Google
 
Web communitydispatch.com



search
For More Current News, Click Here

Search








Clinical Trial Studies
RSS Feed RSS Feed
Last Updated: Nov 25th, 2007 - 10:09:00

                                                                                                                              

Chronic Fatigue Study, Recruiting for Patients for Study


By Clinical Trials


Oct 28, 2006, 12:43


Email this article
 Printer friendly page

 

 

 

 

 

 

 

Study of Ampligen in Chronic Fatigue Syndrome

This study is currently recruiting patients.
Verified by Hemispherx Biopharma September 2005

Sponsored by: Hemispherx Biopharma
Information provided by: Hemispherx Biopharma
ClinicalTrials.gov Identifier: NCT00215813

Purpose

This is an open label study of Ampligen in patients with chronic fatigue syndrome.
Condition Intervention Phase
Chronic Fatigue Syndrome
 Drug: Ampligen (poly I: poly C12U)
Phase III

MedlinePlus related topics:  Chronic Fatigue Syndrome

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Expanded Access Assignment, Safety/Efficacy Study

Official Title: An Open Label Study of Ampligen in Chronic Fatigue Syndrome

Further study details as provided by Hemispherx Biopharma:

An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.

Eligibility

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  1. Diagnosis of myalgic encephalomyelitis (ME) as defined by the 1988 Centers for Disease Control and Prevention (CDC) case definition for chronic fatigue syndrome (CFS) ongoing for >= 12 months (other clinical conditions which could present with similar symptoms must be excluded).
  2. Age Range: >= 18 years old, <= 65 years old.
  3. Males or non-pregnant, non-lactating females: Females must be of non-child bearing potential (either post-menopausal for two years or surgically sterile including tubal ligation) or using an effective means of contraception (birth control pills, intrauterine device, diaphragm). Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test within the four (4) weeks prior to the first study medication infusion. Females of child bearing potential agree to use an effective means of contraception from four (4) weeks prior to the baseline pregnancy test until four (4) weeks after the last study medication infusion.
  4. A reduced quality of life as determined by a Karnofsky performance score (KPS) of >= 20 and <= 60. The KPS must be rounded in increments of ten (10).
  5. Ability to provide written informed consent indicating awareness of the investigational nature of this study.
  6. Documentation (during baseline or historically following onset of CFS/ME) of a negative antinuclear antibody test (ANA) or a negative anti-ds (double-stranded) DNA, a negative rheumatoid factor, and an erythrocyte sedimentation rate (ESR). Documentation during baseline of a normal T4 (or other laboratory evidence that subject is euthyroid) is also required.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00215813

Sharon Conway      215-988-0080    sharon@hemispherx.net


 

Study chairs or principal investigators

Daniel Peterson, M.D.,  Principal Investigator,  Sierra Internal Medicine   
Lucinda Bateman, M.D.,  Principal Investigator,  Fatigue Consultation Clinic   
Charles W. Lapp, M.D.,  Principal Investigator,  Hunter-Hopkins Center, P.A.   

More Information

Study ID Numbers:  AMP 511
Last Updated:  October 24, 2006
Record first received:  September 16, 2005
ClinicalTrials.gov Identifier:  NCT00215813
Health Authority: United States: Food and Drug Administration
 
 
ClinicalTrials.gov: Fatigue Syndrome, Chronic  (National Institutes of Health)
Chronic Fatigue Syndrome  (American Academy of Family Physicians)
Chronic Fatigue Syndrome  (Mayo Foundation for Medical Education and Research)
Teens with Chronic Fatigue Syndrome Benefit from Behavior Therapy  (Nemours Foundation)
Chronic Fatigue Syndrome: Information Resources  (National Institute of Allergy and Infectious Diseases)
Chronic Fatigue Syndrome  (National Center for Infectious Diseases)
Chronic Fatigue Syndrome: Support Groups  (Centers for Disease Control and Prevention)
Possible Causes of Chronic Fatigue Syndrome  (Centers for Disease Control and Prevention)
Chronic Fatigue Syndrome: Treatment Options  (Centers for Disease Control and Prevention)
What's in a Name: Fibromyalgia Versus Chronic Fatigue Syndrome (CFS)  (Arthritis Foundation)
Chronic Fatigue Syndrome: Glossary  (Centers for Disease Control and Prevention)
Diet, Exercise, Stress and the Immune System: What You Can Do to Help  (Cleveland Clinic Foundation)
How CFS and Fibromyalgia Stress Can Make You Gain Weight  (National Fibromyalgia Association)

 


Warning: fopen(/home/agape25/public_html/rssw/rwdcache) [function.fopen]: failed to open stream: Permission denied in /home/agape25/public_html/rssw/rsswload.php on line 175

Warning: fwrite(): supplied argument is not a valid stream resource in /home/agape25/public_html/rssw/rsswload.php on line 176

Warning: fclose(): supplied argument is not a valid stream resource in /home/agape25/public_html/rssw/rsswload.php on line 177

Recent News and Updated Items

Rent a PO Box Without Leaving Your Home
Find, and now rent, a Post Office Box along with the morning cup of coffee or after putting the kids to bed at night. Read More

Airborne Refunds: Eligible Consumers Have 11 Days to Apply for Airborne Refunds
September 15 is the last day for eligible consumers who purchased Airborne products over a six-year period to apply for refunds. Details on eligibility can be found at &#8230;Read More

jen-e.php



 

United States Government News
Latest Headlines


Melamine and Melamine Related Compunds Alert: FDA Issues Interim Safety and Risk Assessment
U.S. and Georgia Business Summit to be held in Tbilisi, Georgia on October 26-28
Foreclosure Prevention: HUD Announces $50 Million In Housing Counseling Grants To Nearly 400 National, State And Local Agencies
U.S. Customs is Hiring: Recruitment Fair October 4
Melamine Alert: Mr. Brown 3-In-1 & and 2-In-1

chronic fatigue syndrome,Chronic Fatigue Syndrome (CFSWG)